Literature DB >> 29955591

Incretin-based therapy and pancreatitis: accumulating evidence and unresolved questions.

Yoshifumi Saisho1.   

Abstract

Entities:  

Year:  2018        PMID： 29955591      PMCID： PMC6015951          DOI： 10.21037/atm.2018.02.24

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  39 in total

1.  GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.

Authors:  Charles Pyke; R Scott Heller; Rikke K Kirk; Cathrine Ørskov; Steffen Reedtz-Runge; Peter Kaastrup; Anders Hvelplund; Linda Bardram; Dan Calatayud; Lotte Bjerre Knudsen
Journal:  Endocrinology       Date:  2014-01-27       Impact factor: 4.736

Review 2.  Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?

Authors:  Roger Yazbeck; Gordon S Howarth; Catherine A Abbott
Journal:  Trends Pharmacol Sci       Date:  2009-11       Impact factor: 14.819

3.  Liraglutide and Renal Outcomes in Type 2 Diabetes.

Authors:  Johannes F E Mann; David D Ørsted; Kirstine Brown-Frandsen; Steven P Marso; Neil R Poulter; Søren Rasmussen; Karen Tornøe; Bernard Zinman; John B Buse
Journal:  N Engl J Med       Date:  2017-08-31       Impact factor: 91.245

4.  Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.

Authors:  Sonal Singh; Hsien-Yen Chang; Thomas M Richards; Jonathan P Weiner; Jeanne M Clark; Jodi B Segal
Journal:  JAMA Intern Med       Date:  2013-04-08       Impact factor: 21.873

5.  Risk of pancreatitis in patients treated with incretin-based therapies.

Authors:  Juris J Meier; Michael A Nauck
Journal:  Diabetologia       Date:  2014-04-11       Impact factor: 10.122

6.  Glucagon-like peptide-1 receptor is present in pancreatic acinar cells and regulates amylase secretion through cAMP.

Authors:  Yanan Hou; Stephen A Ernst; Kaeli Heidenreich; John A Williams
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-11-05       Impact factor: 4.052

7.  A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

Authors:  Xavier Pi-Sunyer; Arne Astrup; Ken Fujioka; Frank Greenway; Alfredo Halpern; Michel Krempf; David C W Lau; Carel W le Roux; Rafael Violante Ortiz; Christine Bjørn Jensen; John P H Wilding
Journal:  N Engl J Med       Date:  2015-07-02       Impact factor: 91.245

8.  Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus.

Authors:  Jean-Luc Faillie; Oriana H Yu; Hui Yin; Dominique Hillaire-Buys; Alan Barkun; Laurent Azoulay
Journal:  JAMA Intern Med       Date:  2016-10-01       Impact factor: 21.873

9.  Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.

Authors:  Belinda Gier; Aleksey V Matveyenko; David Kirakossian; David Dawson; Sarah M Dry; Peter C Butler
Journal:  Diabetes       Date:  2012-01-20       Impact factor: 9.461

10.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse
Journal:  N Engl J Med       Date:  2016-06-13       Impact factor: 176.079
View more
  4 in total

1.  Efficacy and safety of once-weekly exenatide after switching from twice-daily exenatide in patients with type 2 diabetes.

Authors:  Yuusuke Watanabe; Yoshifumi Saisho; Jun Inaishi; Kinsei Kou; Akira Yamauchi; Yasuhiko Kanazawa; Yoshiaki Okubo; Mikiya Tokui; Takatoshi Imai; Rie Murakami; Tami Tsuchiya; Hironobu Sasaki; Tatsuhiro Masaoka; Junichiro Irie; Shu Meguro; Hiroshi Itoh
Journal:  J Diabetes Investig       Date:  2019-10-08       Impact factor: 4.232

2.  The Impact of Incretin-Based Medications on Lipid Metabolism.

Authors:  Habib Yaribeygi; Mina Maleki; Alexandra E Butler; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  J Diabetes Res       Date:  2021-12-29       Impact factor: 4.011

Review 3.  Exenatide Once Weekly for Management of Type 2 Diabetes: A Review.

Authors:  Jun Inaishi; Yoshifumi Saisho
Journal:  Clin Pharmacol       Date:  2022-02-21

Review 4.  Evaluating the Evidence behind the Novel Strategy of Early Combination from Vision to Implementation.

Authors:  Päivi Maria Paldánius
Journal:  Diabetes Metab J       Date:  2020-09-15       Impact factor: 5.376
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.